Key result
Liposomal bupivacaine TAP blocks significantly reduced narcotic use compared to standard bupivacaine (5.06 vs 18.75 mg, P=0.0002) and shortened hospital stay (2.7 vs 3.4 days, P=0.0146).
Why the study?
Concerns regarding narcotic complications, increased hospital length of stay, and healthcare costs motivated comparing liposomal bupivacaine with standard bupivacaine for TAP blocks to evaluate postoperative outcomes.
Does liposomal bupivacaine TAP block reduce narcotic use and improve recovery outcomes compared to standard bupivacaine in patients undergoing laparoscopic colectomy?
Cohort (n=100)
Does liposomal bupivacaine TAP block reduce narcotic use and improve recovery outcomes compared to standard bupivacaine in patients undergoing laparoscopic colectomy?
Absolute Event Rate: 5.06% vs 18.75%
p-value: p=0.0002
Liposomal bupivacaine TAP blocks provide superior pain control, faster return of bowel function, and shorter hospital stays compared to standard bupivacaine in laparoscopic colorectal surgery.
Small cohort leaves open whether liposomal bupivacaine TAP blocks improve outcomes over standard; larger trials needed.
Transversus abdominis plane (TAP) blocks are a safe and effective way to provide immediate postoperative pain relief in surgical patients, and have been shown to decrease narcotic requirements. Concerns about complications of narcotics, increase in hospital length of stay (LOS), and health-care costs make this of particular interest. We compared standard bupivacaine TAP blocks with those carried out using liposomal bupivacaine to evaluate postoperative outcomes. Fifty patients undergoing elective laparoscopic colectomy received laparoscopic liposomal bupivacaine TAP blocks using 80 cc of local anesthetic, and data were collected prospectively during hospitalization. Data collected included amount of narcotic medication used during hospitalization, number of days to ambulation, number of days to bowel function, and LOS. These patients were compared with the last 50 patients recruited to the control/bupivacaine TAP block arm of the study. The same data parameters were collected and all patients were on an enhanced recovery protocol, which included scheduled acetaminophen, ibuprofen, and gabapentin by mouth, as well as clear liquid diet starting on postoperative day zero. Statistical analysis was performed using Student's t test and Fisher's exact test; P < 0.05 was considered statistically significant. Patients treated with liposomal bupivacaine needed less narcotics (5.06 vs 18.75 mg, P = 0.0002), had earlier bowel function (1.7 vs 2.4 days, P = 0.0002), and shorter LOS (2.7 vs 3.4 days, P = 0.0146). Patients undergoing laparoscopic colon resections seem to require fewer narcotics and have better patient outcomes with liposomal bupivacaine TAP blocks. Based on our data, liposomal bupivacaine seems to be superior to bupivacaine for TAP blocks.
No takes yet. Share an insight, caveat, or question.
Guerra et al. (2019) conducted a cohort in Elective laparoscopic colectomy (n=100). Liposomal bupivacaine TAP block vs. Standard bupivacaine TAP block was evaluated on Amount of narcotic medication used during hospitalization (p=0.0002). Liposomal bupivacaine TAP blocks significantly reduced narcotic use compared to standard bupivacaine (5.06 vs 18.75 mg, P=0.0002) and shortened hospital stay (2.7 vs 3.4 days, P=0.0146).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: